Neu­ro com­pa­nies are one of phar­ma's hottest M&A as­sets. But be­hind the scenes, there have been few bid­ders

De­spite be­ing a hot tick­et in bio­phar­ma, neu­ro­science com­pa­nies have at­tract­ed few bid­ders in the multi­bil­lion-dol­lar deals struck in re­cent months.

An SEC fil­ing Mon­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER